STOP-HCV is a Medical Research Council (MRC) funded consortium which aims to use patient information to establish the most effective and cost effective treatments for patients with Hepatitis C Virus.
Professor Ellie Barnes (STOP-HCV lead) talks to the Oxford Centre for Personalised Medicine about the project.
The STOP-HCV consortium is formed of 21 partners representing academia, industry and the Hepatitis C Trust.
Read more about the science we've published.
STOP-HCV Cirrhosis Study reaches 1200 patient recruitment target. 1264 patients (recruited from over 30 hospital sites) are enrolled in the STOP-HCV Cirrhosis Study.
STOP-HCV Consortium publishes findings from its HCV next generation sequencing methods comparison exercise - available online at Journal of Clinical Microbiology.
Viral hepatitis is now the 7th leading cause of death worldwide - findings from the Global Burden of Disease study 2013, published by the Lancet online 6 July 2016.
How to prioritise high-cost HCV treatment? - STOP-HCV investigator Natasha Martin, and others, address this question in an article in the Journal of Hepatology.
STOP-HCV-1 - STOP-HCV investigator, Dr Graham Cooke, has secured funding from the NIHR Efficacy and Mechanism Evaluation programme to undertake a clinical study (STOP-HCV-1) to look at stratification within short-course, all-oral direct-acting antiviral HCV treatment regimes, for Gt1 HCV infected patients with mild liver disease.